- July 12, 2022
- Newsletter
- 617-430-5616
Menu
ADVERTISEMENT
ADVERTISEMENT
Background
In 1895, the association of this disease with pregnancy was developed. Healthy trophoblastic tissue invades the endometrium, resulting in a thick uterine vasculature and a close connection between the mother and the fetus, known as the placenta.
The regulating mechanisms become defective in gestational trophoblastic disorder, resulting in vascular, highly invasive, and metastatic tumors.
It comprises benign and malignant entities such as hydatidiform mole (partial and complete), invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor.
Epidemiology
Asia has a higher prevalence than European or North American populations. Similarly, there are significant regional variations in the prevalence of choriocarcinoma, which ranges from 202 per 100000 pregnancies in China to 2 per 1,00,000 pregnancies in the United States.
The probability of a further partial or complete mole increases to 2% after a molar pregnancy. After two molar pregnancies, the likelihood of developing the third molar pregnancy is 15-20% and changing partners does not reduce the risk.
Anatomy
Pathophysiology
The placenta is the primary source of gestational trophoblastic neoplasia in all forms. Complete moles in the first trimester display an abnormal sprouting villous structure with karyorrhectic stromal debris, trophoblast proliferation, and twisted villous blood vessels.
It can be challenging to morphologically distinguish a non-molar miscarriage from a partial hydatidiform mole because villous dysmorphism can appear without the partial mole’s distinctive trophoblast proliferation. Molar pregnancy may coexist with a healthy pregnancy in rare instances.
Despite the significant chance of spontaneous abortion, 40 to 60% of cases result in live births. In concurrent molar and normal pregnancy, as opposed to a single molar pregnancy, the risk of gestational trophoblastic neoplasm increases from 15 to 46%, respectively. Pregnancy can progress if there are no abnormalities and normal biological and imaging findings.
Etiology
The first cells to divide from a fertilized ovum are trophoblasts; they provide the embryo with nutrition and eventually develop into the fetal section of the placenta. Intermediate trophoblasts, syncytiotrophoblasts, and cytotrophoblasts make up the placental trophoblasts. Molar pregnancies and gestational trophoblastic neoplasia derive from placental trophoblasts.
A complete hydatidiform mole typically develops after one sperm fertilizes an ovum devoid of maternal chromosomes and then repeats its DNA, resulting in a 46XX androgenetic karyotype in which all chromosomes are paternally generated. 10% of fully developed moles are 46XY, the consequence of fertilization by two sperm.
Although mitochondrial DNA is still derived from the mother, nuclear DNA is exclusively paternal. The risk of gestational trophoblastic neoplasia may also be related to hormonal variables. Women who have menarche beyond 12, have a mild menstrual flow, and previously consumed oral contraceptives are more likely to develop the condition.
Genetics
Prognostic Factors
Many metastases are present in most high-risk patients with gestational trophoblastic neoplasia months or years after the original causative pregnancy. The location of the disease affects the signs and symptoms.
Patients with brain metastasis may exhibit convulsions, hemiparesis, or headaches. Unfortunately, the diagnosis can be overlooked because menstrual irregularities are not always present.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
BEP regimen:
30
units
Intravenous (IV)
every week
on days 1, 8, and 15 of a 3-week cycle in combination with etoposide, and cisplatin.
Single agent therapy:
1.25
mg/m^2
Intravenous (IV)
every 2 weeks
High-risk metastatic disease: therapy duration 8 weeks: 0.5 mg IV for 2 days in 2 weeks.
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK562225/
ADVERTISEMENT
In 1895, the association of this disease with pregnancy was developed. Healthy trophoblastic tissue invades the endometrium, resulting in a thick uterine vasculature and a close connection between the mother and the fetus, known as the placenta.
The regulating mechanisms become defective in gestational trophoblastic disorder, resulting in vascular, highly invasive, and metastatic tumors.
It comprises benign and malignant entities such as hydatidiform mole (partial and complete), invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor.
Asia has a higher prevalence than European or North American populations. Similarly, there are significant regional variations in the prevalence of choriocarcinoma, which ranges from 202 per 100000 pregnancies in China to 2 per 1,00,000 pregnancies in the United States.
The probability of a further partial or complete mole increases to 2% after a molar pregnancy. After two molar pregnancies, the likelihood of developing the third molar pregnancy is 15-20% and changing partners does not reduce the risk.
The placenta is the primary source of gestational trophoblastic neoplasia in all forms. Complete moles in the first trimester display an abnormal sprouting villous structure with karyorrhectic stromal debris, trophoblast proliferation, and twisted villous blood vessels.
It can be challenging to morphologically distinguish a non-molar miscarriage from a partial hydatidiform mole because villous dysmorphism can appear without the partial mole’s distinctive trophoblast proliferation. Molar pregnancy may coexist with a healthy pregnancy in rare instances.
Despite the significant chance of spontaneous abortion, 40 to 60% of cases result in live births. In concurrent molar and normal pregnancy, as opposed to a single molar pregnancy, the risk of gestational trophoblastic neoplasm increases from 15 to 46%, respectively. Pregnancy can progress if there are no abnormalities and normal biological and imaging findings.
The first cells to divide from a fertilized ovum are trophoblasts; they provide the embryo with nutrition and eventually develop into the fetal section of the placenta. Intermediate trophoblasts, syncytiotrophoblasts, and cytotrophoblasts make up the placental trophoblasts. Molar pregnancies and gestational trophoblastic neoplasia derive from placental trophoblasts.
A complete hydatidiform mole typically develops after one sperm fertilizes an ovum devoid of maternal chromosomes and then repeats its DNA, resulting in a 46XX androgenetic karyotype in which all chromosomes are paternally generated. 10% of fully developed moles are 46XY, the consequence of fertilization by two sperm.
Although mitochondrial DNA is still derived from the mother, nuclear DNA is exclusively paternal. The risk of gestational trophoblastic neoplasia may also be related to hormonal variables. Women who have menarche beyond 12, have a mild menstrual flow, and previously consumed oral contraceptives are more likely to develop the condition.
Many metastases are present in most high-risk patients with gestational trophoblastic neoplasia months or years after the original causative pregnancy. The location of the disease affects the signs and symptoms.
Patients with brain metastasis may exhibit convulsions, hemiparesis, or headaches. Unfortunately, the diagnosis can be overlooked because menstrual irregularities are not always present.
BEP regimen:
30
units
Intravenous (IV)
every week
on days 1, 8, and 15 of a 3-week cycle in combination with etoposide, and cisplatin.
Single agent therapy:
1.25
mg/m^2
Intravenous (IV)
every 2 weeks
High-risk metastatic disease: therapy duration 8 weeks: 0.5 mg IV for 2 days in 2 weeks.
https://www.ncbi.nlm.nih.gov/books/NBK562225/
In 1895, the association of this disease with pregnancy was developed. Healthy trophoblastic tissue invades the endometrium, resulting in a thick uterine vasculature and a close connection between the mother and the fetus, known as the placenta.
The regulating mechanisms become defective in gestational trophoblastic disorder, resulting in vascular, highly invasive, and metastatic tumors.
It comprises benign and malignant entities such as hydatidiform mole (partial and complete), invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor.
Asia has a higher prevalence than European or North American populations. Similarly, there are significant regional variations in the prevalence of choriocarcinoma, which ranges from 202 per 100000 pregnancies in China to 2 per 1,00,000 pregnancies in the United States.
The probability of a further partial or complete mole increases to 2% after a molar pregnancy. After two molar pregnancies, the likelihood of developing the third molar pregnancy is 15-20% and changing partners does not reduce the risk.
The placenta is the primary source of gestational trophoblastic neoplasia in all forms. Complete moles in the first trimester display an abnormal sprouting villous structure with karyorrhectic stromal debris, trophoblast proliferation, and twisted villous blood vessels.
It can be challenging to morphologically distinguish a non-molar miscarriage from a partial hydatidiform mole because villous dysmorphism can appear without the partial mole’s distinctive trophoblast proliferation. Molar pregnancy may coexist with a healthy pregnancy in rare instances.
Despite the significant chance of spontaneous abortion, 40 to 60% of cases result in live births. In concurrent molar and normal pregnancy, as opposed to a single molar pregnancy, the risk of gestational trophoblastic neoplasm increases from 15 to 46%, respectively. Pregnancy can progress if there are no abnormalities and normal biological and imaging findings.
The first cells to divide from a fertilized ovum are trophoblasts; they provide the embryo with nutrition and eventually develop into the fetal section of the placenta. Intermediate trophoblasts, syncytiotrophoblasts, and cytotrophoblasts make up the placental trophoblasts. Molar pregnancies and gestational trophoblastic neoplasia derive from placental trophoblasts.
A complete hydatidiform mole typically develops after one sperm fertilizes an ovum devoid of maternal chromosomes and then repeats its DNA, resulting in a 46XX androgenetic karyotype in which all chromosomes are paternally generated. 10% of fully developed moles are 46XY, the consequence of fertilization by two sperm.
Although mitochondrial DNA is still derived from the mother, nuclear DNA is exclusively paternal. The risk of gestational trophoblastic neoplasia may also be related to hormonal variables. Women who have menarche beyond 12, have a mild menstrual flow, and previously consumed oral contraceptives are more likely to develop the condition.
Many metastases are present in most high-risk patients with gestational trophoblastic neoplasia months or years after the original causative pregnancy. The location of the disease affects the signs and symptoms.
Patients with brain metastasis may exhibit convulsions, hemiparesis, or headaches. Unfortunately, the diagnosis can be overlooked because menstrual irregularities are not always present.
https://www.ncbi.nlm.nih.gov/books/NBK562225/
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.